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OBJECTIVES: The inclusion of conjugate pneumococcal vaccines to the Regional 
Immunization Program avoids cases, among others, of invasive pneumococcal diseases 
caused by serotypes of Streptococcus pneumoniae contained in the vaccines. Research 
objective was to assess efﬁ ciency of conjugate pneumococcal vaccine- 13 valent 
(PCV13) versus 10 valent (PCV10), under National Health System perspective. 
METHODS: A cost-utility model was developed to estimate cost per quality adjusted 
life-year (QALY) associated to primary bacteriemic, empyema, meningitis and bacte-
riemic pneumonia with vaccine administration in the Autonomous Region of Madrid. 
The estimation of cases to avoid and serotype coverage was based on epidemiologic 
information available at regional level. Additionally to direct protection, the model 
considers the potential indirect effect on the general population. One-way sensitivity 
analyses were performed, including parameters with most uncertainty. RESULTS: 
PCV13 yields 224 QALYs versus 70 QALYs with PCV10. The incremental ratio is 
c16,908/QALY gained. Deterministic sensitivity analysis showed that model results 
are robust, parameter that most inﬂ uence on the results was vaccine indirect effect. 
Reducing PCV13 vaccine schedule from 4 to 3 doses was a dominant strategy. 
CONCLUSIONS: The inclusion of PCV13 is a cost-effective strategy versus PCV10. 
a 3 doses schedule of PCV13 is a dominant option, being a cost-saving measure for 
the National Healthcare System.
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(LPV/R) AND ATAZANAVIR PLUS RITONAVIR (ATV + RTV) REGIMENS 
FOR ANTIRETROVIRAL (ARV) NAÏVE HIV-1 INFECTED PATIENTS 
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No differences in viral load (VL) or CD4+ count at 48 weeks were reported for the 
CASTLE study. However, total cholesterol (TC) levels were elevated in 7% and 18% 
of subjects receiving ATV + RTV and LPV/r, respectively. These measures can predict 
outcomes which affect the future cost of HIV in the Swedish health system. OBJEC-
TIVES: To compare the incremental cost-effectiveness (ICER) and budget impacts for 
a population similar to those enrolled in the CASTLE study for Sweden. METHODS: 
Using a previously published Markov model of HIV disease and 2009 cost data from 
Sweden, we compared the cost/QALY and budget impact of the two ARV regimens. 
Daily drug costs were 160,52 SEK for ATV + RTV and 147,87SEK for LPV/r. Costing 
for other health care resources used a health systems perspective with 2009 inputs 
from www.fass.se and published literature. Costs and QALYs were discounted by 3% 
when calculating ICERs. RESULTS: The CHD risk favored ATV + RTV, resulting in 
a life expectancy increase of 0.031 QALYs (11 days). The cost-effectiveness ratio for 
ATV + RTV for Sweden was 1.251.545 SEK /QALY gained. Three times the Swedish 
GDP in 2008 was 886,670 SEK. Thus the modeled ICER exceeds the WHO criteria 
for cost-effectiveness by 40%. Sensitivity analysis showed the model was mainly 
sensitive to ARV price. Five and 10 years per-patient savings for subjects on the 
LPV/r regimen were estimated to be 21,314 SEK and 32,564 SEK, respectively. 
CONCLUSIONS: Selection of an ATV + RTV based regimen in an ARV-naïve popula-
tion with a CHD risk similar to subjects in the CASTLE study does not appear to be 
a cost-effective use of scarce resources for the cost structure seen in Sweden. The costs 
associated with the very small added CHD risk incurred by LPV/r treatment are more 
than offset by its short and long term cost savings.
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OBJECTIVES: To compare costs for hepatitis C patients by analyzing retrospective 
sick fund claims data. METHODS: A representative panel of 1,193,464 patients from 
several national governmental sick funds were analyzed for 2008. These claims data 
include all direct medical costs from hospitals, materials in the outpatient sector and 
medication (covering 60% of sick fund full costs). Selection criteria for patients were 
at least one conﬁ rmed out- or inpatient diagnosis for acute or chronic hepatitis C 
(ICD-10 GM B17.1 and B18.2). The sample was divided into two groups, those 
treated with pegylated Interferon/Ribavirin ((peg)INF/Rib) (standard of care for 
chronic hepatitis C patients according to German guidelines) and those without 
(identiﬁ ed by ATC Code L03AB and J05AB04). Of these patients all ICD-10 diagnoses 
were grouped by the DxCG software to hierarchical condition categories in order to 
calculate risk scores predicting resource use. The expected cost at the average for all 
insured persons analyzed in this German sick fund panel is represented by a risk score 
of 2.2. Risk scores and co-morbidities were compared with the sick funds average 
means. RESULTS: A total fo 2628 hepatitis C patients were identiﬁ ed (0.2% of the 
panel), 245 with and 2383 without (peg)INF/Rib therapy (treatment rate 9.3%). 
Sixty-two percent of patients with hepatitis C suffered from at least 11 co-morbidities 
(risk score 8.5), while only 27% of all other patients from the panel suffered from at 
least 11 co-morbidities. Further analyses revealed additional pharmacy costs of 
c12,200,- for patients treated with (peg)INF/Rib compared to those without. The risk 
score for the second year after treatment was 5.7 for (peg)INF/Rib-treated versus 8.7 
for (peg)INF/Rib-untreated patients. CONCLUSIONS: A diagnosis of hepatitis C is 
associated with high numbers of co-morbidities and high risk scores. Results suggest 
that treatment lowers risk scores but keeping them substantially above mean. 
INFECTION – Patient-Reported Outcomes Studies
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OBJECTIVES: To determine the reﬁ ll-based adherence rates and to compare the costs 
associated with an under- or over supply of antiretroviral medication. METHODS: A 
non-experimental, quantitative retrospective drug utilization review was performed 
on medicine claims data from one pharmacy beneﬁ t management company. The study 
population were selected from all patients (N = 15 901) who received more than one 
prescription for antiretroviral medication during a 36 consecutive month period (1 
January 2005 to December 2007). An overall reﬁ ll-based adherence rate was calcu-
lated by using the following equation: Reﬁ ll-based adherence rate = (total days of 
antiretroviral items supplied—days supplied at the last reﬁ ll)/(date last claimed—date 
ﬁ rst claimed). (RSA Rand(R)/$US = 6.8595 on 31 December 2007). RESULTS: Reﬁ ll-
based adherence rates were calculated for 41 967 antiretroviral drugs. Less than 50% 
(n = 17 267; 41.15%) of all antiretroviral drugs had acceptable adherence rates 
(between 90% and 110%). Antiretroviral drugs with adherence rates below 90% 
(possibly under-supplied) (n = 7243; 17.26%), accounted for 14.30% (n = R15 829 
876.53) of the total cost of all antiretroviral drugs (N = R110 728, 214.00) while 
those that were possibly over-supplied (n = 17,454; 41.59%) accounted for 25.60% 
(R28 347 266.48). CONCLUSIONS: The calculated reﬁ ll adherence rates indicated 
that most antiretroviral drugs were either possibly over- or under-supplied for the 
speciﬁ c treatment period.
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OBJECTIVES: ART has dramatically increased the life expectancy of HIV-infected 
patients and its adherence has been strongly correlated with viral suppression, reduced 
rates of resistance, an increase in survival, and improved quality of life. The study 
evaluated medication adherence, the association of medication adherence with occupa-
tion and educational status and identiﬁ ed possible causes of non-adherence in HIV-
infected patients after 6 months on ART. METHODS: In a cross-sectional survey, 
medication adherence of 118 HIV-infected patients was evaluated using a self-admin-
istered study-speciﬁ c 16-items questionnaire after 6 months on ART. Patients’ self-
report adherence assessment method was used. Chi square statistics was used to test 
the association of adherence with occupation and education at 95% CI. RESULTS: 
The mean age of the 118 HIV-infected ART patients was 33.89 (95%CI, 29.63–38.15) 
years; and majority (82.2%) were between the ages of 26–45 years; 60.2% were 
females, 80.5% attained secondary education at the least, while 77.1% employed. All 
participants reported being counselled on the beneﬁ ts of ART and medication adher-
ence at ART initiation. On assessment of participants’ knowledge of the beneﬁ ts of 
ART and medication adherence, 92.2% reported correctly, 2.9% reported wrongly 
that ART is a cure for HIV while 4.9% did not respond. Medication adherence level 
reported among participants was 79.1%. Educational status was not associated with 
adherence (p > 0.05) unlike the occupational status which was associated with adher-
ence (P < 0.05). The major reasons reported for non-adherence were busy at work or 
school (33.1%), forgetfulness (15.5%), fasting (12.0%), and travelled or moved away 
from home (10.6%). CONCLUSIONS: The medication adherence level among par-
ticipants was somewhat poor compared to the desired value of >95%; occupational 
status was associated with adherence unlike the educational status. Consequently, 
busy at work or school was a major reason for non-adherence to medication. Routine 
evaluation of medication adherence and intervention in clinical practice is 
recommended.
